

Hull and East Riding Prescribing Committee Minutes – Unconfirmed

Date / Time	Wednesday 24 th November 2021, 1pm
Venue	WEBEX
Chair	Dr S Raise, GP Prescribing Lead, ER
Notes / Action Points	Miss J Morgan
Quorate: Yes / No	Yes – after 1:30

Miss J Morgan, Principal Pharmacist, HUTH
Dr B Ali, GP Prescribing Lead, ER CCG
Mrs E Baggaley, Head of Medicines Service, CHCP
Mr K McCorry, Senior Pharmacist, NECS
Ms M Opoku-Fofie, Senior Pharmacist, HFTH
Ms J Goode, Chief Pharmacist, HUTH
Prof A Morice, Professor of Respiratory Medicine, HUTH – after 1:30
Mrs C Haywood, Professional Development Lead, LPC
Mrs E Wise, Pharmacy Manager, Spire Hull and East Riding

Apologies	Mr P Davis, Strategic Lead Primary Care, Hull, CCG Dr R Schreiber, Professional Secretary LMC
------------------	--

In attendance	Miss S Kendall, Clinical Pharmacist, HUTH
----------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2021.11.01	Apologies	As above				
2021.11.02	Declarations of Interest	None				
2021.11.03	Minutes of the Previous Meeting	Accepted as a true record				
2021.11.04	Matters Arising & Action Tracker	<p>Correspondence Received JM still working with rheumatology to prepare pathway with rituximab without MTX. JM met with rheumatology and pathway in progress for all biologics for January – to update date</p> <p>Feedback From Commissioning Groups KMc and JM to work with CCG to approve MS guideline</p> <p>PG/SCF JM has discussed with Mr Smith and Mr Simms the degarelix SCF and it has now been updated. On website</p> <p>PG/SCF JM/MH to add references to T2DM guideline – discussed at A.O.B.</p> <p>Hydroxychloroquine SCF JM had meeting with Dr Ogunbambi. JM to look at Harrogate pathway and send to Dr Ogunbambi</p> <p>Dementia SCF AOM discussing with memory clinic</p> <p>Traffic Light status WH to update- has been updated</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action Complete</p>	<p>Update next time</p> <p>Update next time</p> <p></p> <p>Update next time</p> <p>Update next time</p> <p>Update next time</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>AOM/JM</p>	<p>Nov 21</p> <p>Nov 21</p> <p>November 21</p> <p>Jan 22</p> <p>Jan 22</p> <p>Nov 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Hyperkalaemia PG/SCF JM updated sections 1b and 1c</p> <p>Treatment of paediatric food allergy EB completed flow chart</p> <p>Sativex SCF Dr Harley agreed to review patients and wait until confirmed commissioning agreement</p> <p>SGLT2i in HF guideline JM has contacted Dr Thackeray to clarify who document is aimed at</p> <p>Correspondence Received JM contacted replied to e-mail from Dr Grover about SCFs for private patients</p>	<p>Action Complete</p> <p>Action Complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>			<p>Nov 21</p> <p>Nov 21</p> <p>Nov 21</p> <p>Nov 21</p> <p>Nov 21</p>
2021.11.05	Traffic Light Status	<p>Bimekizumab – proposed as RED – awaiting updated pathway</p> <p>Tacrolimus suppositories – For chairs approval – Proposed as RED</p> <p>Ateectura (indacaterol/mometasone) Inhaler- proposing as BLUE- specialist asthma team initiation only</p> <p>Dienogest- Proposed as BLUE- Requested pathway</p>				
2021.11.06	Feedback From Commissioning Groups	All previous guidelines/SCF have now been approved.	Noted	No further action		Nov 21
2021.11.07	Prescribing guidelines, shared care frameworks for approval	<p>NEW None</p> <p>UPDATES</p> <p>a) Prescribing anticoagulants JM updated guidance according to NICE AF guideline update; no other changes. The AF pathway had already gone for commissioning.</p> <p>b) CHCP guidance for the administration of subcut furosemide EB presented the updated document, which had been reviewed by the palliative care MDT and heart failure team. SR queried how often it had been used and EB clarified it had rarely been used but had enabled good quality care of patients who needed.</p>	<p>Approved</p> <p>Approved</p>	<p>See actions under 2021.11.07d</p> <p>Update on HERPC website</p>	<p>JM</p> <p>JM</p>	<p>Jan 22</p> <p>Jan 22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>c) Guidance for treatment of acute gout in renal impairment JM updated and added doses of allopurinol, no further changes.</p> <p>d) Dalteparin guidance JM had reviewed guidance that is also in the prescribing anticoagulants document. The only issue relates to the antenatal usage of dalteparin and that all antenatal care sits within the specialist not primary care. Confirm with LMC their position as no representative at meeting. BA confirmed information is useful to have available however needs noting that antenatal/postnatal care sits with the specialist. To keep information in guidance and note in prescribing anticoagulants document that</p> <p>e) Amber SCF Fulvestrant JM added joint and musculoskeletal pain to side effects. No other changes. Approved</p> <p>f) Guideline for treatment of rosacea Treatment of transient facial erythema- Unlicensed use of propranolol. CKS does not believe much evidence- discussed if should be updated to guide towards secondary care as more appropriate.</p>	<p>Approved</p> <p>Ongoing</p> <p>Approved</p> <p>Ongoing</p>	<p>Update on HERPC website</p> <p>Contact LMC Update guidance</p> <p>Update on HERPC website</p> <p>Update pathway</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>Jan 22</p> <p>Jan 22</p> <p>Jan 22</p> <p>Jan 22</p>
2021.11.08	MHRA DSU	<p>Sept 2021 Topical corticosteroids- risk of topical steroid withdrawal reactions Covid-19 vaccines and medicine updates</p> <p>Oct 2021 Tofacitinib- measure to minimise risk of major adverse cardiovascular events and malignancies Chloral hydrate- restriction of paediatric indication</p>	Noted	No further action		Nov 21
2021.09.09	Regional Medicines Optimisation Committee	<p>RMOC shared care guidance: draft shared protocols, consultation 5 (closed)-</p> <p>RMOC shared care guidance: draft shared protocols: consultation 6 (closed)-</p> <p>RMOC North: draft guidance for dealing with requests for shared care from private providers, regional consultation (closed)</p>	Noted	No further action		Nov 21

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2021.09.10	Correspondence Received	Nil				Nov 21
2021.09.11	Primary Care Rebate Scheme	ERoY CCG (a) Clenil Modulite (Beclometasone dipropionate) inhaler (b) Fostair NEXThaler (c) Fostair pMDI (d) Sereflo (Fluticasone with Salmeterol) inhaler Hull CCG (a) Fostair NEXThaler (b) Fostair pMDI (c) Sereflo (Fluticasone with Salmeterol) inhaler	Noted	No further action		
2021.09.12	Additional Minutes for Information	a) MMIG b) HEY D&T c) HTFT DTC d) CHCP e) Formulary Sub Group f) Hull CC Planning & Commissioning	Noted	No further action		Nov 21
2021.09.13	A.O.B	T2DM-KMc raised the draft update to the NICE diabetes guidelines which is due come out in February and now this guideline impinges on approval of the HERPC approved local guideline. Given that NICE will come out so soon the committee agreed not to send guideline for commissioning but to review when NICE publishes this update.	Noted	New action – to review diabetes guideline when published	JM	Feb 22
	Date and Time of Next Meeting	Wednesday 26 th January 2022, 1pm, WEBEX				